EDMUNDO ARTEAGA FERNANDEZ

(Fonte: Lattes)
Índice h a partir de 2011
10
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Assunto: Cardiac & Cardiovascular Systems ×

Resultados de Busca

Agora exibindo 1 - 10 de 16
  • article 0 Citação(ões) na Scopus
    Evaluation of Galectin-3 and Myocardial Fibrosis in Patients with Hypertrophic Cardiomyopathy
    (2019) ANTUNES, Murillo de Oliveira; ARTEAGA-FERNÁNDEZ, Edmundo; FERNANDES, Fabio; SOFFIATTI, Carla David; BUCK, Paula de Cássia; SABINO, Ester Cerdeira; MOREIRA, Carlos Henrique Valente; MADY, Charles
    Abstract Background: Galectin-3 is the designation given to the protein that binds to ß-galactosides, expressed by activated macrophages and described as a cardiac fibrosis mediator. In hypertrophic cardiomyopathy (HCM), myocardial fibrosis is an independent predictor of adverse outcome; however, the association between Galectin-3 and myocardial fibrosis has not been studied in this cardiopathy. Objective: To evaluate the association of Galectin-3 and the presence of myocardial fibrosis in a patient with hypertrophic cardiomyopathy. Methods: Galectin-3 was measured in automated equipment using the Elisa technique in 100 participants divided into two groups: 50 patients with hypertrophic cardiomyopathy and 50 healthy control subjects. All patients with hypertrophic cardiomyopathy underwent magnetic nuclear resonance with the late enhancement technique to investigate myocardial fibrosis. For the statistical analysis, p values < 0.05 were considered statistically significant. Results: Galectin-3 levels were low and did not show significant differences between patients with hypertrophic cardiomyopathy and the control group, 10.3 ± 3.1 ng/dL and 11.3 ± 2.6 ng/dL (p = 0.12) respectively. Myocardial fibrosis was a common finding and was identified in 84% (42/50) of patients with HCM, but no differences were observed between Galectin-3 levels when comparing patients with and without fibrosis, 10.3 ± 2.4 ng/dL and 10.1 ± 2.1 ng/dL (p = 0.59). Conclusion: The results did not show an association between Galectin-3 and myocardial fibrosis in patients with hypertrophic cardiomyopathy, suggesting that non-inflammatory mechanisms of myocardial fibrosis formation and cardiac remodeling are involved in this cardiopathy.
  • article 7 Citação(ões) na Scopus
    Clinical predictors of a positive genetic test in hypertrophic cardiomyopathy in the Brazilian population
    (2014) MARSIGLIA, Julia Daher Carneiro; CREDIDIO, Flavia Laghi; OLIVEIRA, Theo Gremen Mimary de; REIS, Rafael Ferreira; ANTUNES, Murillo de Oliveira; ARAUJO, Aloir Queiroz de; PEDROSA, Rodrigo Pinto; BARBOSA-FERREIRA, Joao Marcos Bemfica; MADY, Charles; KRIEGER, Jose Eduardo; ARTEAGA-FERNANDEZ, Edmundo; PEREIRA, Alexandre Costa
    Background: Hypertrophic cardiomyopathy is a genetic autosomal dominant disease characterized by left ventricular hypertrophy. The molecular diagnosis is important but still expensive. This work aimed to find clinical predictors of a positive genetic test in a Brazilian tertiary centre cohort of index cases with HCM. Methods: In the study were included patients with HCM clinical diagnosis. For genotype x phenotype comparison we have evaluated echocardiographic, electrocardiographic, and nuclear magnetic resonance measures. All patients answered a questionnaire about familial history of HCM and/or sudden death. beta myosin heavy chain, myosin binding protein C, and troponin T genes were sequenced for genetic diagnosis. Results: The variables related to a higher probability of a positive genetic test were familial history of HCM, higher mean heart frequency, presence of NSVT and lower age. Probabilities of having a positive molecular genetic test were calculated from the final multivariate logistic regression model and were used to identify those with a higher probability of a positive molecular diagnosis. Conclusions: We developed an easy and fast screening method that takes into account only clinical data that can help to select the patients with a high probability of positive genetic results from molecular sequencing of Brazilian HCM patients.
  • article 58 Citação(ões) na Scopus
    The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death
    (2019) FREITAS, Pedro; FERREIRA, Antonio Miguel; ARTEAGA-FERNANDEZ, Edmundo; ANTUNES, Murrilo de Oliveira; MESQUITA, Joao; ABECASIS, Joao; MARQUES, Hugo; SARAIVA, Carla; MATOS, Daniel Nascimento; RODRIGUES, Rita; CARDIM, Nuno; MADY, Charles; ROCHITTE, Carlos Eduardo
    Background Identifying the patients with hypertrophic cardiomyopathy (HCM) in whom the risk of sudden cardiac death (SCD) justifies the implantation of a cardioverter-defibrillator (ICD) in primary prevention remains challenging. Different risk stratification and criteria are used by the European and American guidelines in this setting. We sought to evaluate the role of cardiovascular magnetic resonance (CMR) late gadolinium enhancement (LGE) in improving these risk stratification strategies. Methods We conducted a multicentric retrospective analysis of HCM patients who underwent CMR for diagnostic confirmation and/or risk stratification. Eligibility for ICD was assessed according to the HCM Risk-SCD score and the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) algorithm. The amount of LGE was quantified (LGE%) and categorized as 0%, 0.1-10%, 10.1-19.9% and >= 20%. The primary endpoint was a composite of SCD, aborted SCD, sustained ventricular tachycardia (VT), or appropriate ICD discharge. Results A total of 493 patients were available for analysis (58% male, median age 46 years). LGE was present in 79% of patients, with a median LGE% of 2.9% (IQR 0.4-8.4%). The concordance between risk assessment by the HCM Risk-SCD, ACCF/AHA and LGE was relatively weak. During a median follow-up of 3.4 years (IQR 1.5-6.8 years), 23 patients experienced an event (12 SCDs, 6 appropriate ICD discharges and 5 sustained VTs). The amount of LGE was the only independent predictor of outcome (adjusted HR: 1.08; 95% CI: 1.04-1.12; p < 0.001) after adjustment for the HCM Risk-SCD and ACCF/AHA criteria. The amount of LGE showed greater discriminative power (C-statistic 0.84; 95% CI: 0.76-0.91) than the ACCF/AHA (C-statistic 0.61; 95% CI: 0.49-0.72; p for comparison < 0.001) and the HCM Risk-SCD (C-statistic 0.68; 95% CI: 0.59-0.78; p for comparison = 0.006). LGE was able to increase the discriminative power of the ACCF/AHA and HCM Risk-SCD criteria, with net reclassification improvements of 0.36 (p = 0.021) and 0.43 (p = 0.011), respectively. Conclusions The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorithm in the identification of HCM patients at increased risk of SCD and reclassifies a relevant proportion of patients.
  • conferenceObject
    Lack of Effect of Simvastatin on Structural Remodeling in Animal Model of Chagas Cardiomyopathy
    (2012) IANNI, Barbara M.; RAMIRES, Felix J. A.; SALEMI, Vera M. C.; FERNANDES, Fabio; OLIVEIRA, Adriana M.; PESSOA, Fernanda G.; FONSECA, Keila C. B.; ARTEAGA, Edmundo; NASTARI, Luciano; MADY, Charles
    Purpose: Chagas cardiomyopathy(CM) is characterized by a large amount of fibrosis and inflamation. As simvastatin (simva) has anti-inflamatory effects, we hypothetized that it could be an important drug in the treatment of patients with CM. The purpose was to evaluate simva in the myocardium remodeling and inflammation in na animal model of CM. Methods: 123 hamsters were divided: C-controls(25), CSimva-controls with simva 10mg/Kg/day(25), Simva1-infected treated from beginning with the same dose of simva(25), Simva2-infected treated after 4 months(24); Infect-untreated(24). Follow-up of 10 months. Interstitial collagen volume fraction (ICVF) RV and LV measured using videomorphometry and picrosirius red stained heart. Metalloproteinase9 (MMP9) was obtained by zymography. Gene expression of TNFalpha, IFNgamma, IL10 by real time PCR and ΔCt. Survival by Kaplan-Meier and log rank. Comparison between groups by Kruskal-Wallis; p≤0.05. Results: Infected animals Simva1=189±133 days Simva2=150±124; Infect=138±123) lived less than controls (C=257±80; CSimva=283±58)(p≤0.05) with no difference among infected. ICVF-RV(%) was greater in infected groups (Simva1=3.88±1.14, Simva2=2.22±0.64; Infect=4.38±0.83) than in controls C=1.12±0.31; CSimva=2.18±0.73)(p≤0.05)with no difference among infected groups. ICVF-LV(%) was greater in infected animals (Simva1=1.83±1.01, Simva2=1.52±0.93; Infect=3.01±0.66) than in controls (C=0.68±0.31; CSimva=0.81±0.28)(p≤0.05) with no difference among infected. MMP9 was higher in infected groups (Simva1=2394±2441, Simva2=5673±4091; Infect=2392±2042) compared to controls (C=954±2332; CSimva=454±1123)(p≤0.05) with no difference among infected. TNFalpha did not have difference among infected groups (Simva1=5.33±3.66, Simva2=4.44±2.17; Infect=6.13±3.24). IFNgamma in infected groups (Simva1=5.47±3.56, Simva2=4.46±2.08; Infect=4.21±2.09) was higher than in controls (C=8.50±2.59; CSimva=6.84±2.53)(p≤0.05) with no difference among infected. IL10 in infected animals (Simva1=9.07±4.62, Simva2=7.76±4.77; Infect=8.11±4.48) did not have difference and the values were greater than controls (C=14.11±4.40; CSimva=12.55±3.90)(p≤0.05). Conclusions: Simva did not attenuate deposition of interstitial collagen, did not change dynamics of collagen degradation, did not decrease inflammation, and did not reduce mortality.
  • article 1 Citação(ões) na Scopus
    Prognostic Evaluation of Microvolt T-Wave Alternans in Hypertrophic Cardiomyopathy: 9-year Clinical Follow-up
    (2023) ANTUNES, Murillo Oliveira; ARTEAGA-FERNANDEZ, Edmundo; SAMESIMA, Nelson; PEREIRA FILHO, Horacio Gomes; MATSUMOTO, Afonso Yoshikiro; VERRIER, Richard L.; PASTORE, Carlos Alberto; MADY, Charles
    Background: Sudden cardiac death (SCD) resulting from ventricular arrhythmia is the main complication of hypertrophic cardiomyopathy (HCM). Microvolt T-wave alternans (MTWA) is associated with the occurrence of ventricular arrhythmias in several heart diseases, but its role in HCM remains uncertain. Objective: To evaluate the association of MTWA with the occurrence of SCD or potentially fatal ventricular arrhythmias in HCM patients in a long-term follow-up. Avaliacao Prognostica da Microalternancia da onda T na Cardiomiopatia Hipertrofica em um Seguimento Clinico de 9 anos Prognostic Evaluation of Microvolt T-Wave Alternans in Hypertrophic Cardiomyopathy: 9-year Clinical Follow-up Oliveira Antunes,1,2 Edmundo Arteaga-Fernandez,1 Nelson Samesima,1 Horacio Gomes Pereira Afonso Yoshikiro Matsumoto,3 Richard L. Verrier,4 Carlos Alberto Pastore,1 Charles Mady1 do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo,1 Sao Paulo, SP - Brasil Universidade Sao Francisco,2 Braganca Paulista, SP - Brasil Group,3 Sao Paulo, SP - Brasil Israel Deaconess Medical Center,4 Boston - EUA
  • article 53 Citação(ões) na Scopus
    Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy
    (2013) SHIOZAKI, Afonso Akio; SENRA, Tiago; ARTEAGA, Edmund; MARTINELLI FILHO, Martino; PITA, Cristiane Guedes; AVILA, Luis Francisco R.; PARGA FILHO, Jose Rodrigues; MADY, Charles; KALIL-FILHO, Roberto; BLUEMKE, David A.; ROCHITTE, Carlos Eduardo
    Background: Myocardial fibrosis (MF) occurs in up to 80% of subjects with asymptomatic or mildly symptomatic hypertrophic cardiomyopathy (HCM) and can constitute an arrhythmogenic substrate for re-entrant, life-threatening ventricular arrhythmias in predisposed persons. Objective: The aim was to investigate whether MF detected by delayed enhancement cardiac CT is predictive of ventricular tachycardia (VT) and fibrillation (VF) that require appropriate therapy by an implantable cardioverter defibrillator (ICD) in patients with HCM. Methods: Twenty-six patients with HCM with previously (for at least 1 year) implanted ICD underwent MF evaluation by cardiac CT. MF was quantified by myocardial delayed enhanced cardiac CT. Data on ICD firing were recorded every 3 months after ICD implantation. Risk factors for sudden cardiac death in patients with HCM were evaluated in all patients. Results: MF was present in 25 of 26 patients (96%) with mean fibrosis mass of 20.5 +/- 15.8 g. Patients with appropriate ICD shocks for VF/VT had significantly greater MF mass than patients without (29.10 +/- 19.13 g vs 13.57 +/- 8.31 g; P = .01). For a MF mass of at least 18 g, sensitivity and specificity for appropriate ICD firing were 73% (95% CI, 49%-88%) and 71% (95% CI, 56%-81%), respectively. Kaplan-Meier curves indicated a significantly greater VF/VT event rate in patients with MF mass >= 18 g than in patients with MF <18 g (P = .02). In the Cox regression analysis, the amount of MF was independently associated with VF/VT in ICD-stored electrograms. Conclusion: The mass of MF detected by cardiac CT in patients with HCM at high risk of sudden death was associated with appropriate ICD firings.
  • article 19 Citação(ões) na Scopus
    1st Brazilian Positioning on the Impact of Sleep Disorders on Cardiovascular Diseases of the Brazilian Society of Cardiology
    (2018) DRAGER, Luciano E.; LORENZI-FILHO, Geraldo; CINTRA, Fatima Dumas; PEDROSA, Rodrigo P.; BITTENCOURT, Lia R. A.; POYARES, Dalva; CARVALHO, Carolina Gonzaga; MOURA, Sonia Maria Guimaraes Pereira Togeiro; SANTOS-SILVA, Rogerio; BRUIN, Pedro F. C. de; GEOVANINI, Glaucylara R.; ALBUQUERQUE, Felipe N.; OLIVEIRA, Vvercules Antonio Alves de; MOREIRA, Gustavo A.; UENO, Linda Massako; NERBASS, Flavia Baggio; RONDON, Maria Urbana Pinto Brandao; BARBOSA, Fine Rozaria Ferreira; BERTOLAMI, Adriana; PAOLA, Angelo Amato Vincenzo de; MARQUES, Betania Braga Silva; RIZZI, Camila Futado; NEGRAO, Carlos Eduardo; UCHOA, Carlos Henrique Gomes; MAKI-NUNES, Cristiane; MARTINEZ, Denis; FERNANDEZ, Edmundo Arteaga; MAROJA, Fabrizio U.; ALMEIDA, Fernanda R.; TROMBETTA, Ivani C.; STORTI, Luciana J.; BORTOLOTTO, Luiz Aparecido; MELLO, Marco Tulio de; BORGES, Melania Aparecida; ANDERSEN, Monica Levy; PORTILHO, Natanael de Paula; MACEDO, Paula; ALVES, Rosana; TUFIK, Sergio; FAGONDES, Simone C.; RISSO, Thais Telles
  • article 2 Citação(ões) na Scopus
    Intramyocardial Adrenergic Activation in Chagasic Cardiomyopathy and Coronary Artery Disease
    (2011) NASTARI, Luciano; RAMIRES, Felix Jose Alvarez; SALEMI, Vera Maria Cury; IANNI, Barbara Maria; FERNANDES, Fabio; STRUNZ, Celia Maria; ARTEAGA, Edmundo; MADY, Charles
    Background: Myocardial norepinephrine is altered in left ventricular impairment. In patients with Chagas' cardiomyopathy (CC), this issue has not been addressed. Objective: To determine the level of myocardial norepinephrine in patients with CC and compare it in patients with coronary artery disease, and to relate myocardial norepinephrine to left ventricular ejection fraction (WEE). Methods: We studied 39 patients with CC, divided into group 1: 21 individuals with normal LVEF and group 2: 18 individuals with decreased LVEF. Seventeen patients with coronary artery disease were divided into group 3: 12 individuals with normal LVEF and group 4: 5 individuals with decreased LVEF. Two-dimensional echocardiography was used to measure LVEF. Myocardial norepinephrine was determined by high-performance liquid chromatography. Results: Myocardial norepinephrine in CC with and without ventricular dysfunction was 1.3 1.3 and 6.1 +/- 4.2 pg/mu g noncollagen protein, respectively (p<0.0001); in coronary artery disease with and without ventricular dysfunction, it was 3.3 +/- 3.0 and 9.8 +/- 4.2 pg mu g noncollagen protein, respectively (p<0.0001). A positive correlation was found between LVEF and myocardial norepinephrine concentration in the patients with Chagas' cardiomyopathy (p<0.01, r = 0.57) and also in those with coronary artery disease (p<0.01, r=0.69). A significant difference was demonstrated between norepinephrine concentrations in patients with normal WEE (groups 1 and 3; p = 0.0182), hut no difference was found in patients with decreased LVEF (groups 2 and 4; p = 0.1467). Conclusion: In patients with Chagas' cardiomyopathy and normal global ejection fraction there is an early cardiac dolma lion, when compared to coronary artery disease patients. (Arq Bras Cardiol 2011; 96(2): 99-106)
  • article 1 Citação(ões) na Scopus
    Prevention of Sudden Death in Hypertrophic Cardiomyopathy
    (2018) ARTEAGA-FERNANDEZ, Edmundo; ANTUNES, Murillo de Oliveira
  • article 2 Citação(ões) na Scopus
    Rare association of left ventricular non-compaction and hypertrophic cardiomyopathy
    (2020) HOTTA, Viviane Tiemi; MONGE, Nathalia Maria Segovia; FERNANDES, Fabio; ARTEAGA-FERNANDEZ, Edmundo